KCAS talks biomarker strategy development

By Claire Videau and Gareth Macdonald

- Last updated on GMT

Related tags: Food and drug administration, Pharmacology, Clinical trial

KCAS talks biomarker strategy development
Biomarkers are critical to discovery and can help pharmaceutical firms make development a more efficient and cost effective process accord to bioanalysis services provider KCAS.

But, as KCAS’ Proveen Dass told Outsourcing-pharma, developing an effective biomaker strategy across the entire pharmaceutical development cycle can be a considerable challenge.

He explained that, whether in the lab, during preclinical development or in patient selection for clinical trials, appropriate use of biomaker analysis is the critical factor in helping drugmakers accelerate development and cut costs.

Dr Dass added that, while US Food and Drug Administration (FDA) guidelines mean biomarker validation can be a lengthily process, dividing development according to the specific stage of the process can make it more efficient.

For example, in early stages of drug development we need a qualified assay, yes no categorical data, as compared to a fully validated assay in clinical trials.”

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us


View more